BDX vs CYTK · P/E 34, rev $21.84B vs rev $28.6M
Becton Dickinson and Company (BDX) versus Cytokinetics Inc (CYTK) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
Cytokinetics Inc (CYTK) is a biotechnology company listed on US.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
Latest reported CYTK revenue for 2026-06-30 was $28.6M. Net income was -$198.8M. Revenue was up 47.9% from 2026-03-31 to 2026-06-30. CYTK currently screens at market cap $4.05B.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. CYTK currently screens at market cap $4.05B.
Not investment advice. Open the BDX and CYTK stock pages for the full models.
Not investment advice.